Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Oxford Biodynamics PLC
OXBOFOxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. The company provides EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation, and monitoring of 3D genomic biomarkers to diagnose patients. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom. Address: 3140 Rowan Place, Oxford, United Kingdom, OX4 2WB
Analytics
Zielpreis von Wall Street
13 544.37 GBXKGV
–Dividendenrendite
–Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen OXBOF
Dividenden-Analyse OXBOF
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
–Verlauf der Dividende OXBOF
Bewertung der Aktie OXBOF
Finanzen OXBOF
Ergebnisse | 2019 | Dynamik |